Have a feature idea you'd love to see implemented?
Let us know!
NVAX Novavax Inc
Price (delayed)
$8.04
Market cap
$1.29B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.19
Enterprise value
$937.02M
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III
Highlights
Novavax's EPS has surged by 65% YoY and by 19% QoQ
Novavax's net income has increased by 48% YoY and by 3.2% from the previous quarter
NVAX's quick ratio has surged by 62% year-on-year but it is down by 9% since the previous quarter
Novavax's equity has increased by 22% YoY but it has decreased by 22% QoQ
NVAX's gross profit is down by 17% YoY and by 10% QoQ
The revenue has contracted by 16% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of NVAX
Market
Valuations
Earnings
Shares outstanding
160.18M
Market cap
$1.29B
Enterprise value
$937.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.06
Revenue
$885.19M
EBIT
-$263.13M
EBITDA
-$216.36M
Free cash flow
-$112.35M
Per share
Balance sheet
Liquidity
EPS
-$2.19
Free cash flow per share
-$0.7
Book value per share
-$3.29
Revenue per share
$5.53
TBVPS
$9.91
Total assets
$1.71B
Total liabilities
$2.24B
Debt
$233.31M
Equity
-$526.44M
Working capital
-$77.32M
Debt to equity
-0.44
Current ratio
0.93
Quick ratio
0.86
Net debt/EBITDA
1.62
Margins
Efficiency
Dividend
EBITDA margin
-24.4%
Gross margin
63.7%
Net margin
-32.2%
Operating margin
-34.1%
Return on assets
-17.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-49.5%
Return on sales
-29.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVAX stock price
How has the Novavax stock price performed over time
Intraday
-0.25%
1 week
11.36%
1 month
-20.71%
1 year
50.28%
YTD
67.5%
QTD
-36.34%
Financial performance
How have Novavax's revenue and profit performed over time
Revenue
$885.19M
Gross profit
$564.15M
Operating income
-$301.42M
Net income
-$284.86M
Gross margin
63.7%
Net margin
-32.2%
Novavax's operating income has soared by 52% YoY but it has decreased by 2.9% from the previous quarter
Novavax's net income has increased by 48% YoY and by 3.2% from the previous quarter
The operating margin has increased by 43% year-on-year but it has declined by 15% since the previous quarter
Novavax's net margin has increased by 38% YoY but it has decreased by 8% QoQ
Growth
What is Novavax's growth rate over time
Valuation
What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
1.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.06
Novavax's EPS has surged by 65% YoY and by 19% QoQ
Novavax's equity has increased by 22% YoY but it has decreased by 22% QoQ
NVAX's P/S is 88% below its 5-year quarterly average of 12.3 but 12% above its last 4 quarters average of 1.3
The revenue has contracted by 16% YoY and by 10% from the previous quarter
Efficiency
How efficient is Novavax business performance
NVAX's return on assets is up by 44% year-on-year and by 3.9% since the previous quarter
Novavax's return on sales has increased by 42% YoY but it has decreased by 7% QoQ
Dividends
What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVAX.
Financial health
How did Novavax financials performed over time
Novavax's total assets is 24% lower than its total liabilities
NVAX's quick ratio has surged by 62% year-on-year but it is down by 9% since the previous quarter
The current ratio has increased by 35% year-on-year but it has declined by 11% since the previous quarter
Novavax's debt is 144% higher than its equity
NVAX's debt to equity is down by 33% year-on-year but it is up by 19% since the previous quarter
Novavax's equity has increased by 22% YoY but it has decreased by 22% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.